المؤلفون: Reutens A.T., Colman P.G., Davis T.M.E., Ekinci E.I., Fulcher G., Hamblin P.S., Kotowicz M.A., MacIsaac R.J., Morbey C., Simmons D., Soldatos G., Wittert G., Wu T., Cooper M.E., Shaw J.E., De Livera A.M., Bach L.A., Salim A., Thomas M., Jandeleit-Dahm K.

مصطلحات الفهرس: randomized controlled trial, risk assessment, treatment duration, trough concentration, unspecified side effect/si [Side Effect], urinary excretion, urinary tract infection/dt [Drug Therapy], albumin/ec [Endogenous Compound], alfentanil/cb [Drug Combination], angiotensin receptor antagonist/dt [Drug Therapy], antibiotic agent/dt [Drug Therapy], astemizole/cb [Drug Combination], cisapride/cb [Drug Combination], clarithromycin/cb [Drug Combination], conivaptan/cb [Drug Combination], creatinine/ec [Endogenous Compound], cyclosporine/cb [Drug Combination], dihydroergotamine/cb [Drug Combination], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], ergotamine/cb [Drug Combination], fentanyl/cb [Drug Combination], indinavir plus ritonavir/cb [Drug Combination], itraconazole/cb [Drug Combination], ketoconazole/cb [Drug Combination], lopinavir plus ritonavir/cb [Drug Combination], pimozide/cb [Drug Combination], placebo, quinidine/cb [Drug Combination], rapamycin/cb [Drug Combination], reduced nicotinamide adenine dinucleotide phosphate oxidase/ec [Endogenous Compound], ritonavir/cb [Drug Combination], setanaxib/ae [Adverse Drug Reaction], setanaxib/ct [Clinical Trial], setanaxib/cb [Drug Combination], setanaxib/cm [Drug Comparison], setanaxib/cr [Drug Concentration], setanaxib/dt [Drug Therapy], setanaxib/pd [Pharmacology], tacrolimus/cb [Drug Combination], telaprevir/cb [Drug Combination], terfenadine/cb [Drug Combination], voriconazole/cb [Drug Combination], setanaxib/pk [Pharmacokinetics], clinical evaluation, clinical protocol, adult, aged, albuminuria/dt [Drug Therapy], animal experiment, antibiotic therapy, article, controlled study, creatinine blood level, creatinine urine level, diabetic nephropathy/dt [Drug Therapy], diabetic patient, double blind procedure, drug blood level, drug efficacy, drug safety, drug withdrawal, estimated glomerular filtration rate, female, human, insulin dependent diabetes mellitus/dt [Drug Therapy], major clinical study, male, microalbuminuria, mouse, multicenter study, nonhuman, outcome assessment, patient compliance, phase 2 clinical trial, physician, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29385
Contemporary Clinical Trials
LibKey Link

المؤلفون: Leung R., Seifman M.A., Rozen W.M., Hunter-Smith D.J., Reilly D., Miller G.

مصطلحات الفهرس: soft tissue defect/su [Surgery], very elderly, antibiotic agent/dt [Drug Therapy], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/pv [Special Situation for Pharmacovigilance], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clarithromycin/pv [Special Situation for Pharmacovigilance], fusidate sodium/cb [Drug Combination], fusidate sodium/dt [Drug Therapy], fusidate sodium/pv [Special Situation for Pharmacovigilance], prednisolone/pv [Special Situation for Pharmacovigilance], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], rifampicin/pv [Special Situation for Pharmacovigilance], reconstructive surgery, aged, anterolateral thigh flap, antibiotic therapy, artery anastomosis, Buruli ulcer/dt [Drug Therapy], Buruli ulcer/su [Surgery], case report, clinical article, debridement, fasciocutaneous flap, female, human, male, Mycobacterium ulcerans, outcome assessment, priority journal, review, skin necrosis, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36212
European Journal of Plastic Surgery
Click here for full text options
LibKey Link

المؤلفون: Leung R., Seifman M.A., Rozen W.M., Hunter-Smith D.J., Reilly D., Miller G.

مصطلحات الفهرس: soft tissue defect/su [Surgery], very elderly, antibiotic agent/dt [Drug Therapy], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/pv [Special Situation for Pharmacovigilance], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clarithromycin/pv [Special Situation for Pharmacovigilance], fusidate sodium/cb [Drug Combination], fusidate sodium/dt [Drug Therapy], fusidate sodium/pv [Special Situation for Pharmacovigilance], prednisolone/pv [Special Situation for Pharmacovigilance], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], rifampicin/pv [Special Situation for Pharmacovigilance], reconstructive surgery, aged, anterolateral thigh flap, antibiotic therapy, artery anastomosis, Buruli ulcer/dt [Drug Therapy], Buruli ulcer/su [Surgery], case report, clinical article, debridement, fasciocutaneous flap, female, human, male, Mycobacterium ulcerans, outcome assessment, priority journal, review, skin necrosis, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36212
European Journal of Plastic Surgery
LibKey Link

المؤلفون: Horne S., Jenkin G., Athan E., O'Brien D.P., Buntine J., Steffen C.M., McDonald A., Deborah Friedman N., Johnson P.D.R., Callan P.P., Hughes A.

مصطلحات الفهرس: amikacin/cb [Drug Combination], drug dose reduction, fine needle aspiration biopsy, health care cost, human, hyperthermic therapy, morbidity, paradoxical drug reaction, polymerase chain reaction, practice guideline, recommended drug dose, World Health Organization, amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/po [Oral Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], moxifloxacin/po [Oral Drug Administration], prednisolone/dt [Drug Therapy], rifampicin/dt [Drug Therapy], rifampicin/po [Oral Drug Administration], streptomycin/cb [Drug Combination], streptomycin/dt [Drug Therapy], rifampicin/cb [Drug Combination], quinoline derived antiinfective agent/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], article, Australia, Buruli ulcer/dt [Drug Therapy], Buruli ulcer/pc [Prevention], Buruli ulcer/su [Surgery], Buruli ulcer/th [Therapy], clinical practice, disease transmission, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/41646
Medical Journal of Australia
Click here for full text options
LibKey Link

المؤلفون: Horne S., Jenkin G., Athan E., O'Brien D.P., Buntine J., Steffen C.M., McDonald A., Deborah Friedman N., Johnson P.D.R., Callan P.P., Hughes A.

مصطلحات الفهرس: amikacin/cb [Drug Combination], drug dose reduction, fine needle aspiration biopsy, health care cost, human, hyperthermic therapy, morbidity, paradoxical drug reaction, polymerase chain reaction, practice guideline, recommended drug dose, World Health Organization, amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], ciprofloxacin/po [Oral Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], moxifloxacin/po [Oral Drug Administration], prednisolone/dt [Drug Therapy], rifampicin/dt [Drug Therapy], rifampicin/po [Oral Drug Administration], streptomycin/cb [Drug Combination], streptomycin/dt [Drug Therapy], rifampicin/cb [Drug Combination], quinoline derived antiinfective agent/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], article, Australia, Buruli ulcer/dt [Drug Therapy], Buruli ulcer/pc [Prevention], Buruli ulcer/su [Surgery], Buruli ulcer/th [Therapy], clinical practice, disease transmission, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/41646
Medical Journal of Australia
Click here for full text options
LibKey Link

المؤلفون: Kamm M.A., Prideaux L., Allen P.B., Moore G., De Cruz P.

مصطلحات الفهرس: clinical practice, colorectal cancer, Crohn disease/dt [Drug Therapy], Crohn disease/su [Surgery], diagnostic procedure, disease activity, drug efficacy, drug megadose, dysplasia, enteric feeding, erythema, follow up, gold standard, histology, hospitalization, inflammation, information retrieval, intestine endoscopy, maintenance therapy, monotherapy, non invasive procedure, nuclear magnetic resonance imaging, outcome assessment, post hoc analysis, postoperative period, priority journal, prognosis, recurrence risk, relapse, remission, review, treatment duration, ulcer, wound healing, adalimumab/dt [Drug Therapy], aminosalicylic acid, azathioprine/dt [Drug Therapy], mercaptopurine/dt [Drug Therapy], mesalazine, methotrexate/dt [Drug Therapy], metronidazole/dt [Drug Therapy], naltrexone/dt [Drug Therapy], natalizumab/dt [Drug Therapy], ornidazole/ct [Clinical Trial], ornidazole/dt [Drug Therapy], placebo, prednisolone/dt [Drug Therapy], rifabutin/cb [Drug Combination], rifabutin/dt [Drug Therapy], ileocolonoscopy, mucosal healing, loading drug dose, azathioprine/iv [Intravenous Drug Administration], biological marker/ec [Endogenous Compound], budesonide/dt [Drug Therapy], calgranulin/ec [Endogenous Compound], certolizumab pegol/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clofazimine/cb [Drug Combination], clofazimine/dt [Drug Therapy], infliximab/dt [Drug Therapy], infliximab/iv [Intravenous Drug Administration], lactoferrin/ec [Endogenous Compound], abdominal surgery, biological therapy, cancer risk, capsule endoscopy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27671
Click here for full text options
LibKey Link

المؤلفون: Kamm M.A., Prideaux L., Allen P.B., Moore G., De Cruz P.

مصطلحات الفهرس: clinical practice, colorectal cancer, Crohn disease/dt [Drug Therapy], Crohn disease/su [Surgery], diagnostic procedure, disease activity, drug efficacy, drug megadose, dysplasia, enteric feeding, erythema, follow up, gold standard, histology, hospitalization, inflammation, information retrieval, intestine endoscopy, maintenance therapy, monotherapy, non invasive procedure, nuclear magnetic resonance imaging, outcome assessment, post hoc analysis, postoperative period, priority journal, prognosis, recurrence risk, relapse, remission, review, treatment duration, ulcer, wound healing, adalimumab/dt [Drug Therapy], aminosalicylic acid, azathioprine/dt [Drug Therapy], mercaptopurine/dt [Drug Therapy], mesalazine, methotrexate/dt [Drug Therapy], metronidazole/dt [Drug Therapy], naltrexone/dt [Drug Therapy], natalizumab/dt [Drug Therapy], ornidazole/ct [Clinical Trial], ornidazole/dt [Drug Therapy], placebo, prednisolone/dt [Drug Therapy], rifabutin/cb [Drug Combination], rifabutin/dt [Drug Therapy], ileocolonoscopy, mucosal healing, loading drug dose, azathioprine/iv [Intravenous Drug Administration], biological marker/ec [Endogenous Compound], budesonide/dt [Drug Therapy], calgranulin/ec [Endogenous Compound], certolizumab pegol/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clofazimine/cb [Drug Combination], clofazimine/dt [Drug Therapy], infliximab/dt [Drug Therapy], infliximab/iv [Intravenous Drug Administration], lactoferrin/ec [Endogenous Compound], abdominal surgery, biological therapy, cancer risk, capsule endoscopy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27671
LibKey Link

المؤلفون: Kerr T.G., Tee W., Midolo P.D., Lambert J.R.

مصطلحات الفهرس: Gram negative infection/dr [Drug Resistance], Gram negative infection/dt [Drug Therapy], Helicobacter pylori, human, minimum inhibitory concentration, priority journal, antibiotic agent/cb [Drug Combination], antibiotic agent/it [Drug Interaction], clarithromycin/cb [Drug Combination], clarithromycin/it [Drug Interaction], clarithromycin/dt [Drug Therapy], ranitidine bismuth citrate/cb [Drug Combination], ranitidine bismuth citrate/it [Drug Interaction], ranitidine bismuth citrate/dt [Drug Therapy], tetracycline/cb [Drug Combination], tetracycline/it [Drug Interaction], tetracycline/dt [Drug Therapy], antibiotic agent/dt [Drug Therapy], article, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33648
Click here for full text options
LibKey Link

المؤلفون: Fyfe J.A.M., Johnson P.D.R., Charles P.G.P., Ghosh N., Clark B.M., Martinello M., Jenkin G.A., Lavender C.J., Globan M.

مصطلحات الفهرس: article, Australia, bacterial strain, bacterium culture, bacterium isolation, Buruli ulcer/di [Diagnosis], Buruli ulcer/dt [Drug Therapy], Buruli ulcer/su [Surgery], female, geography, human, male, molecular epidemiology, Mycobacterium ulcerans, nonhuman, nucleotide sequence, priority journal, real time polymerase chain reaction, single nucleotide polymorphism, skin surgery, travel, variable number of tandem repeat, ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], adult, clinical article, aged, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28200
Click here for full text options
LibKey Link

المؤلفون: Lange C.G., Brodt R.H., Woolley I.J.

مصطلحات الفهرس: mycobacterium intracellulare avium, opportunistic infection/co [Complication], opportunistic infection/dt [Drug Therapy], opportunistic infection/ep [Epidemiology], opportunistic infection/et [Etiology], opportunistic infection/pc [Prevention], osteomyelitis/co [Complication], Pneumocystis pneumonia/co [Complication], Pneumocystis pneumonia/dt [Drug Therapy], Pneumocystis pneumonia/pc [Prevention], recurrent infection/co [Complication], recurrent infection/dt [Drug Therapy], recurrent infection/ep [Epidemiology], secondary prevention, amikacin/cb [Drug Combination], amikacin/dt [Drug Therapy], antivirus agent/it [Drug Interaction], antivirus agent/dt [Drug Therapy], azithromycin/ct [Clinical Trial], azithromycin/dt [Drug Therapy], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], clarithromycin/ct [Clinical Trial], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clofazimine/cb [Drug Combination], clofazimine/dt [Drug Therapy], cotrimoxazole/dt [Drug Therapy], cytochrome P450/ec [Endogenous Compound], ethambutol/ct [Clinical Trial], ethambutol/cb [Drug Combination], ethambutol/dt [Drug Therapy], isoniazid/cb [Drug Combination], isoniazid/dt [Drug Therapy], macrolide/cb [Drug Combination], recurrent infection/pc [Prevention], macrolide/dt [Drug Therapy], placebo, rifabutin/ct [Clinical Trial], rifabutin/cb [Drug Combination], rifabutin/dt [Drug Therapy], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], macrolide/it [Drug Interaction], review, recurrent infection/et [Etiology], acquired immune deficiency syndrome, antibiotic prophylaxis, atypical mycobacteriosis/co [Complication], atypical mycobacteriosis/dt [Drug Therapy], atypical mycobacteriosis/ep [Epidemiology], atypical mycobacteriosis/et [Etiology], atypical mycobacteriosis/pc [Prevention], clinical trial, highly active antiretroviral therapy, human, Human immunodeficiency virus infection/dt [Drug Therapy], lymphadenopathy/co [Complication], lymphocyte count, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32613
Click here for full text options
LibKey Link

المؤلفون: Lambert J.R., Dev A.T.

مصطلحات الفهرس: diarrhea/si [Side Effect], disease association, drug choice, drug efficacy, drug potentiation, drug tolerability, dyspepsia/dt [Drug Therapy], dyspepsia/si [Side Effect], eradication therapy, gastritis/co [Complication], gastritis/et [Etiology], gastroduodenal ulcer/co [Complication], gastroduodenal ulcer/dt [Drug Therapy], gastroduodenal ulcer/et [Etiology], gastroduodenal ulcer/si [Side Effect], Gram negative infection/di [Diagnosis], Gram negative infection/dt [Drug Therapy], Gram negative infection/ep [Epidemiology], Gram negative infection/et [Etiology], Helicobacter pylori, histology, human, mucosa associated lymphoid tissue lymphoma/co [Complication], mucosa associated lymphoid tissue lymphoma/et [Etiology], nausea/si [Side Effect], pathogenesis, patient compliance, pseudomembranous colitis/si [Side Effect], review, serodiagnosis, side effect, stomach adenocarcinoma/co [Complication], stomach adenocarcinoma/et [Etiology], taste disorder/si [Side Effect], amoxicillin/cb [Drug Combination], amoxicillin/do [Drug Dose], amoxicillin/dt [Drug Therapy], bismuth/ae [Adverse Drug Reaction], bismuth/do [Drug Dose], bismuth/it [Drug Interaction], metronidazole/ae [Adverse Drug Reaction], metronidazole/cb [Drug Combination], metronidazole/do [Drug Dose], metronidazole/dt [Drug Therapy], nonsteroid antiinflammatory agent/ae [Adverse Drug Reaction], nonsteroid antiinflammatory agent/dt [Drug Therapy], omeprazole/cb [Drug Combination], omeprazole/do [Drug Dose], omeprazole/it [Drug Interaction], omeprazole/dt [Drug Therapy], pantoprazole/cb [Drug Combination], pantoprazole/do [Drug Dose], pantoprazole/dt [Drug Therapy], proton pump inhibitor/cb [Drug Combination], proton pump inhibitor/do [Drug Dose], proton pump inhibitor/it [Drug Interaction], proton pump inhibitor/dt [Drug Therapy], ranitidine bismuth citrate/do [Drug Dose], ranitidine bismuth citrate/dt [Drug Therapy], tetracycline/do [Drug Dose], tetracycline/dt [Drug Therapy], unclassified drug, urea/ec [Endogenous Compound], helidac/do [Drug Dose], helidac/dt [Drug Therapy], endoscope, bismuth/dt [Drug Therapy], bismuth citrate/do [Drug Dose], bismuth citrate/dt [Drug Therapy], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], histamine H2 receptor antagonist/dt [Drug Therapy], lansoprazole/cb [Drug Combination], lansoprazole/dt [Drug Therapy], antibiotic resistance, antibiotic therapy, breath analysis, carcinogenesis/co [Complication], clinical feature, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28480
Medical Journal of Australia
Click here for full text options
LibKey Link

المؤلفون: Holmes N.E., Korman T.M., Dendle C., Hodgkinson M.

مصطلحات الفهرس: human, immediate type hypersensitivity, letter, Mycobacterium chelonei, priority journal, skin nodule/dt [Drug Therapy], skin nodule/et [Etiology], skin ulcer/dt [Drug Therapy], skin ulcer/et [Etiology], amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/ad [Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/do [Drug Dose], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], doxycycline/ae [Adverse Drug Reaction], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], imipenem/dt [Drug Therapy], imipenem/iv [Intravenous Drug Administration], linezolid/ae [Adverse Drug Reaction], linezolid/dt [Drug Therapy], moxifloxacin/dt [Drug Therapy], rifampicin/dt [Drug Therapy], clinical protocol, absence of side effects/si [Side Effect], aged, anamnesis, antibiotic therapy, bacterial skin disease/dt [Drug Therapy], bacterial skin disease/et [Etiology], case report, desensitization, diarrhea/si [Side Effect], drug choice, drug dose increase, drug substitution, drug withdrawal, female, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31608
Click here for full text options
LibKey Link

المؤلفون: Midolo P.D., Ward P., Rerksuppaphol S., Hardikar W.

مصطلحات الفهرس: gastroscopy, gender, Helicobacter pylori, human, incidence, male, minimum inhibitory concentration, nonhuman, priority journal, prospective study, statistical significance, strain identification, symptomatology, treatment outcome, amoxicillin/cb [Drug Combination], amoxicillin/cm [Drug Comparison], amoxicillin/dt [Drug Therapy], amoxicillin/pd [Pharmacology], antiinfective agent/cm [Drug Comparison], bismuth/cb [Drug Combination], bismuth/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/cm [Drug Comparison], clarithromycin/dt [Drug Therapy], clarithromycin/pd [Pharmacology], metronidazole/cb [Drug Combination], metronidazole/cm [Drug Comparison], metronidazole/dt [Drug Therapy], metronidazole/pd [Pharmacology], omeprazole/cb [Drug Combination], omeprazole/dt [Drug Therapy], tetracycline/cm [Drug Comparison], e test, sensitivity analysis, adolescent, age, antibiotic resistance, antibiotic sensitivity, article, bacterium isolation, child, childhood disease/dr [Drug Resistance], childhood disease/dt [Drug Therapy], clinical article, clinical feature, demography, eradication therapy, ethnology, Europe, female, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32665
LibKey Link

المؤلفون: Kerr T.G., Tee W., Midolo P.D., Lambert J.R.

مصطلحات الفهرس: Gram negative infection/dr [Drug Resistance], Gram negative infection/dt [Drug Therapy], Helicobacter pylori, human, minimum inhibitory concentration, priority journal, antibiotic agent/cb [Drug Combination], antibiotic agent/it [Drug Interaction], clarithromycin/cb [Drug Combination], clarithromycin/it [Drug Interaction], clarithromycin/dt [Drug Therapy], ranitidine bismuth citrate/cb [Drug Combination], ranitidine bismuth citrate/it [Drug Interaction], ranitidine bismuth citrate/dt [Drug Therapy], tetracycline/cb [Drug Combination], tetracycline/it [Drug Interaction], tetracycline/dt [Drug Therapy], antibiotic agent/dt [Drug Therapy], article, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33648
LibKey Link

المؤلفون: Fyfe J.A.M., Johnson P.D.R., Charles P.G.P., Ghosh N., Clark B.M., Martinello M., Jenkin G.A., Lavender C.J., Globan M.

مصطلحات الفهرس: article, Australia, bacterial strain, bacterium culture, bacterium isolation, Buruli ulcer/di [Diagnosis], Buruli ulcer/dt [Drug Therapy], Buruli ulcer/su [Surgery], female, geography, human, male, molecular epidemiology, Mycobacterium ulcerans, nonhuman, nucleotide sequence, priority journal, real time polymerase chain reaction, single nucleotide polymorphism, skin surgery, travel, variable number of tandem repeat, ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], adult, clinical article, aged, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28200
LibKey Link

المؤلفون: Lange C.G., Brodt R.H., Woolley I.J.

مصطلحات الفهرس: mycobacterium intracellulare avium, opportunistic infection/co [Complication], opportunistic infection/dt [Drug Therapy], opportunistic infection/ep [Epidemiology], opportunistic infection/et [Etiology], opportunistic infection/pc [Prevention], osteomyelitis/co [Complication], Pneumocystis pneumonia/co [Complication], Pneumocystis pneumonia/dt [Drug Therapy], Pneumocystis pneumonia/pc [Prevention], recurrent infection/co [Complication], recurrent infection/dt [Drug Therapy], recurrent infection/ep [Epidemiology], secondary prevention, amikacin/cb [Drug Combination], amikacin/dt [Drug Therapy], antivirus agent/it [Drug Interaction], antivirus agent/dt [Drug Therapy], azithromycin/ct [Clinical Trial], azithromycin/dt [Drug Therapy], ciprofloxacin/cb [Drug Combination], ciprofloxacin/dt [Drug Therapy], clarithromycin/ct [Clinical Trial], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], clofazimine/cb [Drug Combination], clofazimine/dt [Drug Therapy], cotrimoxazole/dt [Drug Therapy], cytochrome P450/ec [Endogenous Compound], ethambutol/ct [Clinical Trial], ethambutol/cb [Drug Combination], ethambutol/dt [Drug Therapy], isoniazid/cb [Drug Combination], isoniazid/dt [Drug Therapy], macrolide/cb [Drug Combination], recurrent infection/pc [Prevention], macrolide/dt [Drug Therapy], placebo, rifabutin/ct [Clinical Trial], rifabutin/cb [Drug Combination], rifabutin/dt [Drug Therapy], rifampicin/cb [Drug Combination], rifampicin/dt [Drug Therapy], macrolide/it [Drug Interaction], review, recurrent infection/et [Etiology], acquired immune deficiency syndrome, antibiotic prophylaxis, atypical mycobacteriosis/co [Complication], atypical mycobacteriosis/dt [Drug Therapy], atypical mycobacteriosis/ep [Epidemiology], atypical mycobacteriosis/et [Etiology], atypical mycobacteriosis/pc [Prevention], clinical trial, highly active antiretroviral therapy, human, Human immunodeficiency virus infection/dt [Drug Therapy], lymphadenopathy/co [Complication], lymphocyte count, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32613
LibKey Link

المؤلفون: Lambert J.R., Dev A.T.

مصطلحات الفهرس: diarrhea/si [Side Effect], disease association, drug choice, drug efficacy, drug potentiation, drug tolerability, dyspepsia/dt [Drug Therapy], dyspepsia/si [Side Effect], eradication therapy, gastritis/co [Complication], gastritis/et [Etiology], gastroduodenal ulcer/co [Complication], gastroduodenal ulcer/dt [Drug Therapy], gastroduodenal ulcer/et [Etiology], gastroduodenal ulcer/si [Side Effect], Gram negative infection/di [Diagnosis], Gram negative infection/dt [Drug Therapy], Gram negative infection/ep [Epidemiology], Gram negative infection/et [Etiology], Helicobacter pylori, histology, human, mucosa associated lymphoid tissue lymphoma/co [Complication], mucosa associated lymphoid tissue lymphoma/et [Etiology], nausea/si [Side Effect], pathogenesis, patient compliance, pseudomembranous colitis/si [Side Effect], review, serodiagnosis, side effect, stomach adenocarcinoma/co [Complication], stomach adenocarcinoma/et [Etiology], taste disorder/si [Side Effect], amoxicillin/cb [Drug Combination], amoxicillin/do [Drug Dose], amoxicillin/dt [Drug Therapy], bismuth/ae [Adverse Drug Reaction], bismuth/do [Drug Dose], bismuth/it [Drug Interaction], metronidazole/ae [Adverse Drug Reaction], metronidazole/cb [Drug Combination], metronidazole/do [Drug Dose], metronidazole/dt [Drug Therapy], nonsteroid antiinflammatory agent/ae [Adverse Drug Reaction], nonsteroid antiinflammatory agent/dt [Drug Therapy], omeprazole/cb [Drug Combination], omeprazole/do [Drug Dose], omeprazole/it [Drug Interaction], omeprazole/dt [Drug Therapy], pantoprazole/cb [Drug Combination], pantoprazole/do [Drug Dose], pantoprazole/dt [Drug Therapy], proton pump inhibitor/cb [Drug Combination], proton pump inhibitor/do [Drug Dose], proton pump inhibitor/it [Drug Interaction], proton pump inhibitor/dt [Drug Therapy], ranitidine bismuth citrate/do [Drug Dose], ranitidine bismuth citrate/dt [Drug Therapy], tetracycline/do [Drug Dose], tetracycline/dt [Drug Therapy], unclassified drug, urea/ec [Endogenous Compound], helidac/do [Drug Dose], helidac/dt [Drug Therapy], endoscope, bismuth/dt [Drug Therapy], bismuth citrate/do [Drug Dose], bismuth citrate/dt [Drug Therapy], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], histamine H2 receptor antagonist/dt [Drug Therapy], lansoprazole/cb [Drug Combination], lansoprazole/dt [Drug Therapy], antibiotic resistance, antibiotic therapy, breath analysis, carcinogenesis/co [Complication], clinical feature, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28480
Medical Journal of Australia
LibKey Link

المؤلفون: Holmes N.E., Korman T.M., Dendle C., Hodgkinson M.

مصطلحات الفهرس: human, immediate type hypersensitivity, letter, Mycobacterium chelonei, priority journal, skin nodule/dt [Drug Therapy], skin nodule/et [Etiology], skin ulcer/dt [Drug Therapy], skin ulcer/et [Etiology], amikacin/dt [Drug Therapy], amikacin/iv [Intravenous Drug Administration], clarithromycin/ae [Adverse Drug Reaction], clarithromycin/ad [Drug Administration], clarithromycin/cb [Drug Combination], clarithromycin/do [Drug Dose], clarithromycin/dt [Drug Therapy], clarithromycin/po [Oral Drug Administration], doxycycline/ae [Adverse Drug Reaction], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], imipenem/dt [Drug Therapy], imipenem/iv [Intravenous Drug Administration], linezolid/ae [Adverse Drug Reaction], linezolid/dt [Drug Therapy], moxifloxacin/dt [Drug Therapy], rifampicin/dt [Drug Therapy], clinical protocol, absence of side effects/si [Side Effect], aged, anamnesis, antibiotic therapy, bacterial skin disease/dt [Drug Therapy], bacterial skin disease/et [Etiology], case report, desensitization, diarrhea/si [Side Effect], drug choice, drug dose increase, drug substitution, drug withdrawal, female, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31608
LibKey Link

المؤلفون: Birch C., Druce J., Bardin P., Hart D., Irving L., Ryan N., Charles P.G.P., Whitby M., Fuller A.J., Stirling R., Wright A.A., Korman T.M., Holmes P.W., Christiansen K.J., Waterer G.W., Pierce R.J.P., Mayall B.C., Armstrong J.G., Catton M.G., Nimmo G.R., Johnson B., Hooy M., Grayson M.L., Grayson L., Johnson P., Munckhof W., Looke D., Garske L., Playford G., Spelman D., Kotsimbos T., Holmes P., Heath C.

مصطلحات الفهرس: ceftriaxone/dt [Drug Therapy], penicillin G/dt [Drug Therapy], roxithromycin/cb [Drug Combination], roxithromycin/dt [Drug Therapy], community acquired pneumonia/dt [Drug Therapy], community acquired pneumonia/ep [Epidemiology], community acquired pneumonia/et [Etiology], controlled clinical trial, controlled study, female, Haemophilus influenzae, human, influenza, Influenza virus, Legionella, major clinical study, male, Moraxella catarrhalis, mortality, multicenter study, Mycoplasma pneumoniae, outcome assessment, Parainfluenza virus, Picornavirus, Pneumonia Severity Index, polymerase chain reaction, practice guideline, priority journal, prospective study, Pseudomonas aeruginosa, Respiratory syncytial pneumovirus, respiratory virus, serodiagnosis, Staphylococcus aureus, Streptococcus pneumoniae, treatment failure, virus infection, amoxicillin/cb [Drug Combination], amoxicillin/dt [Drug Therapy], azithromycin/cb [Drug Combination], azithromycin/dt [Drug Therapy], cefotaxime/cb [Drug Combination], cefotaxime/dt [Drug Therapy], ceftriaxone/cb [Drug Combination], cefuroxime/cb [Drug Combination], cefuroxime/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], erythromycin/cb [Drug Combination], erythromycin/dt [Drug Therapy], hypertensive factor/dt [Drug Therapy], macrolide/cb [Drug Combination], macrolide/dt [Drug Therapy], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], penicillin G/cb [Drug Combination], Adenovirus, adult, antibiotic resistance, article, artificial ventilation, Australia, bacterial infection, Chlamydophila, clinical assessment, clinical trial, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31549
Clinical Infectious Diseases
Click here for full text options
LibKey Link

المؤلفون: Birch C., Druce J., Bardin P., Hart D., Irving L., Ryan N., Charles P.G.P., Whitby M., Fuller A.J., Stirling R., Wright A.A., Korman T.M., Holmes P.W., Christiansen K.J., Waterer G.W., Pierce R.J.P., Mayall B.C., Armstrong J.G., Catton M.G., Nimmo G.R., Johnson B., Hooy M., Grayson M.L., Grayson L., Johnson P., Munckhof W., Looke D., Garske L., Playford G., Spelman D., Kotsimbos T., Holmes P., Heath C.

مصطلحات الفهرس: ceftriaxone/dt [Drug Therapy], penicillin G/dt [Drug Therapy], roxithromycin/cb [Drug Combination], roxithromycin/dt [Drug Therapy], community acquired pneumonia/dt [Drug Therapy], community acquired pneumonia/ep [Epidemiology], community acquired pneumonia/et [Etiology], controlled clinical trial, controlled study, female, Haemophilus influenzae, human, influenza, Influenza virus, Legionella, major clinical study, male, Moraxella catarrhalis, mortality, multicenter study, Mycoplasma pneumoniae, outcome assessment, Parainfluenza virus, Picornavirus, Pneumonia Severity Index, polymerase chain reaction, practice guideline, priority journal, prospective study, Pseudomonas aeruginosa, Respiratory syncytial pneumovirus, respiratory virus, serodiagnosis, Staphylococcus aureus, Streptococcus pneumoniae, treatment failure, virus infection, amoxicillin/cb [Drug Combination], amoxicillin/dt [Drug Therapy], azithromycin/cb [Drug Combination], azithromycin/dt [Drug Therapy], cefotaxime/cb [Drug Combination], cefotaxime/dt [Drug Therapy], ceftriaxone/cb [Drug Combination], cefuroxime/cb [Drug Combination], cefuroxime/dt [Drug Therapy], clarithromycin/cb [Drug Combination], clarithromycin/dt [Drug Therapy], doxycycline/cb [Drug Combination], doxycycline/dt [Drug Therapy], erythromycin/cb [Drug Combination], erythromycin/dt [Drug Therapy], hypertensive factor/dt [Drug Therapy], macrolide/cb [Drug Combination], macrolide/dt [Drug Therapy], moxifloxacin/cb [Drug Combination], moxifloxacin/dt [Drug Therapy], penicillin G/cb [Drug Combination], Adenovirus, adult, antibiotic resistance, article, artificial ventilation, Australia, bacterial infection, Chlamydophila, clinical assessment, clinical trial, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31549
Clinical Infectious Diseases
LibKey Link